Background. Secreting different adipocytokines, adipose tissue plays an important role in health and disease. Upon omega-3 consumption, changes in the secretion of adipose tissue and its effects on glycemic profile are a controversial subject at the present time.
intRODuCtiOn
White adipose tissue (WAT) consists of vascular, nervous and adipose tissues with scattered macrophages, fibroblasts and series of cells that secret a number of adipocytokines such as leptin, adiponectin, resistin, tumor necrosis factor-alpha (TNF-α) and interleukin -6 (IL-6) (1, 2). Overall, these adipocytokines affect health and play important roles in energy homeostasis, progression of insulin resistance, type II diabetes and hyperlipidemia (3) (4) (5) . At present, studies point to the relationship between white mature adipose tissue as an important endocrine organ that secretes adiponectin (6, 7) and type 2 diabetes (4, (8) (9) (10) (11) . As white adipose tissue has a role in regulating the metabolism of lipids and carbohydrates (4, 12) , changes in the expression of genes (13) that have a role in the secretion of cytokines will result in changes in weight, lipid and carbohydrate metabolism and the related diseases (14) . However, changes in the secretion of adipose tissues after Omega-3 consumption and its effects on glycemic profile are of interest among researchers carrying out clinical trials on type II diabetes (15) (16) (17) (18) . Therefore, this research was done to evaluate the effects of Eicosapentaenoic Acid (EPA), as an Omega-3 fatty acid, with and without vitamin E on adiponectin and serum glycemic profiles in patients with type II diabetes mellitus.
MAteRiAlS AnD MethODS
The study population consisted of 136 patients with type II diabetes mellitus recruited from the Diabetes Clinic affiliated to Kashan University of Medical Sciences in the first quarter of 2008. Being identified as a patient with diabetes one had to be treated by oral hypoglycemic agents or have a fasting plasma glucose concentration > 7.0 mmol/L.
The inclusion criteria included being 35-50 years old, male or female, with a BMI = 25-30 kg/m 2 , having been diagnosed with diabetes for a duration of 2-15 years, having no recent (past year) digestive, renal, microalbuminuria (19) , hepatic, cardiovascular, thyroid or respiratory diseases, or a diagnosis of cancer. Additionally, being nonalcoholic, non-smoker, and having no history of drug abuse, ongoing pregnancy or breast-feeding were the other criteria for inclusion in the study.
At the beginning of the study, we recruited 136 patients, but 127 patients completed the study successfully. Two subjects withdrew because of digestive intolerance to the supplements, two for unplanned journeys, two for incompliance to the program, one for appendicectomy, one for immigration and one subject could not attend the center for blood measurement in the final stage.
Study design
In this placebo-controlled, double blind study with parallel designs, subjects were randomly (balanced permuted blocks) assigned to one of four groups after signing an informed consent form. The individuals filled a demographic questionnaire and reported a 24-hour dietary recall. They reported the dietary recall two more times during the study. Three 24-hour food recalls (on Sundays, Wednesdays and Fridays) were collected before and after the study.
The four groups included:
For every placebo group we prepared a Corn oil pearl in similar shape and dose. Therefore, when we were providing 2 grams of EPA, we provided a 2-gram Corn oil placebo pearl or when we were providing 400 units of vitamin E we provided 0.4 gram of Corn oil placebo pearl. Therefore, we had four groups consisting of:
(P) group = Receiving placebo or 2.4 grams of corn oil (2 grams of corn oil + 0.4 gram of corn oil);
(EPA) group = The EPA group receiving two grams of EPA supplement + placebo (0.4 g);
(Vit E) group = The vitamin E group receiving 400 IU of vitamin E supplement + placebo (2 g);
(EPA+Vit E) group = The EPA plus vitamin E group receiving two grams of EPA supplement + 400 IU of vitamin E.
The individuals were told to take the supplements postprandially (after lunch and dinner) without immediately drinking hot fluids. The regimen continued for 12 weeks, while the patients took their antidiabetic agents as before. The subjects were also recommended not to change their diet or their physical activity until the end of the study. The subjects' weight, BMI and blood pressure were measured and they were referred to laboratory at the beginning and at end of the 12 th week. All the subjects were closely followed up every two weeks for weight, BP and BMI measurements and the way they were taking the supplements and continuing their routine diet and physical activity. They were also called/phoned/contacted for making sure they were following the recommendations throughout the study period. The patients' weight and height were measured by a Seca height and weight measuring scale (Germany, Seca GmbH & Co. KG) and BMI was calculated using weight/height m² formula. Tehran University of Medical Sciences supported the study and the respective Ethics Committee approved the study proposal.
Supplement characteristics
Plus EPA (500 mg) pearls containing pure EPA (99%) were obtained from Minami Nutrition, Belgium and Vitamin E pearls containing 400 IU of α-Tocopherol acetate (natural; d) from Dana Pharmaceutical Company in Tabriz, Iran. The placebo content (corn oil) was very similar to that of the participants' dietary regimen. All the supplements were conforming to ethical points of view in taking such substances.
Blood collection
From each participant, five milliliters of venous blood were drawn into empty and EDTA vacuum tubes after an overnight fast. Serum and plasma samples were stored at -70°C until assayed. Samples were protected from the natural light. To measure serum adiponectin concentration, ELISA kits (Ani biotech OY-ADIP025-Orgenium Laboratories Division-FINLAND) were used. FBS was measured by Glucose Oxidase using Pars Azmoon Kit (TehranIran). HbA1c concentration was assessed by kit (NYCOCARD -1042184 -Rapid Diagnostic PVT.LTD -INDIA) and evaluated by a spectrophotometer. Insulin was measured by a Radioimmunoassay kit (Immunotech -Insulin (e) IRMA KIT IM3210-FRANCE). Insulin Sensitivity Index or Quicki was calculated by the following formula (20): 1/[log insulin (µIU/mL) + log glucose (ml/dL)] = Insulin Sensitivity Index HOMA-IR was calculated by the following formula (21):
Statistical analysis
The data were analyzed using SPSS (version 16.0 for Windows, Polar Engineering and Consulting, USA) by general linear models to assess the effects of EPA, E, or EPA+E relative to the placebo. All variables were tested for normality by using histograms and Kolmogorov-Smirnov statistics. If the data distribution was not normal, either before or after the intervention, they were log transformed for statistical analysis. We used paired t-test to evaluate any differences before and after treatment within groups. By the analysis of covariance (ANCOVA) was used to identify any differences in biochemical parameters between groups after intervention, adjusting for baseline measurements and covariates. We later used the Bonferroni test to evaluate the amounts of change in different layers of the variables to determine the mean amounts of change in the main group. Significance levels were adjusted for multiple comparisons by using Bonferroni method. Differences between the four groups were considered significant when P<0.05. All values were reported as means ± SEMs except for the demographic data of the patients at baseline, which are reported as means ± SDs or as percentage (%).
ReSultS

Study population
One hundred and twenty seven patients completed the study successfully without any changes in their diet or fluctuations in taking the Table 1 . Characteristics of participants in the four groups at baseline x ± SD or %. There were no significant differences between the four groups at baseline (by UNIANOVA). Chi-square test was used to detect differences in gender profile between the groups. [EPA = Eicosapentaenoic acid; E = Vitamin E]. supplements. Baseline characteristics of the four groups confirmed that they had been well-matched for the entry criteria shown in Tables 1 and 2 .
There were no significant differences between the groups in either the type or number of oral hypoglycemic medications (for the type of oral hypoglycemic medications we used Chisquared distribution; for the number of oral hypoglycemic medications we used ANOVA test). The subjects also took oral hypoglycemic agents in the form of biguanides with (and) sulfonylureas (76%), sulfonylureas (16%) or biguanides agents (8%). Antidiabetic agents were taken unchanged during the intervention in all groups. Mean ± SD. Baseline and Post intervention measures were compared by paired t-test (within groups) and between groups by UNIANOVA. There were no significant differences between the groups in any of the dietary nutrients at baseline and no significant changes during the intervention. [EPA = Eicosapentaenoic acid; E = Vitamin E].
Energy and macronutrient intakes
Evidence of adherence to the diets was confirmed by analyzing the diet recall records and supplement counts.
Analysis of diet records indicated that total energy and major macronutrient and micronutrient intakes were not significantly different between the groups at baseline ( Table 2 ) and did not change significantly in any of the groups during the intervention.
Serum
Adiponectin and glycemic indexes measurements
There were no significant differences either among the mean concentration of adiponectin, FBS, HbA1c, insulin, Quicki index and HOMA-IR or in the duration of diabetes diagnosis at the beginning of the study.
In comparison with baseline concentrations, serum adiponectin had a significant increase of 23.6% and 18.1% after intervention in both groups of EPA+E and EPA groups respectively (Table 3 , Fig. 1 ).
A meaningful difference in serum adiponectin concentration was noted among the study groups after omitting the variables BMI (baseline and after intervention), PUFA intake, fasting insulin, leptin and the baseline ADP level after 3 months. The difference in EPA+E and EPA group, respectively, (Table 3) .
HbA1c decreased 6.6% and 7.8% in EPA+E and EPA groups, respectively, in comparison with the baseline values after three months (Fig. 2) . A meaningful difference was seen in HbA1c concentration after omitting the baseline level at the end of the study. The difference in EPA+E and EPA groups included, respectively, a decrease of 83.6% and 11.6% in comparison with E group (Table 3) . Serum fasting insulin concentration decreased 22.8% in EPA+E group in comparison with its baseline levels after three months of intervention. A meaningful difference was seen in serum fasting insulin concentration after omitting the effects of BMI, waist hip ratio (WHR), and the baseline fasting insulin levels after the study period. The difference in EPA+E and EPA groups included a decrease of 20.5% and 1.4%, respectively, in comparison with the Placebo group (Table 3) .
A meaningful difference was seen in Quicki index after omitting the effects of variables BMI, WHR, ADP, and the baseline Quicki index after three months of intervention. The difference in EPA+E and EPA groups included an increase of 7.8% and 5.2%, respectively, in comparison with the Placebo group (Table 3) .
HOMA-IR index had a decrease of 21.4% and 22.2% in EPA+E and EPA groups and an increase of 25 % and 21.4% in E and Placebo groups, respectively, in comparison with their baseline concentrations after the study (Fig. 3) . A meaningful difference was noted in HOMA-IR index after omitting BMI, WHR, ADP, and the baseline HOMA-IR index after the study. The difference included a decrease of 32% in EPA+E and EPA groups in comparison with the Placebo group (Table 3) . We also measured changes in BMI, Waist Hip Ratio (WHR) and the participants' weight and found that in groups on EPA supplementation, weight and BMI had decreased, respectively, 1.9% (P<0.001) and 0.9% (P=0.05) but WHR did not undergo significant changes.
DiSCuSSiOn
As we aimed to evaluate the effects of omega 3 fatty acid on the secretion of adipose tissue and also its effect on metabolism of sugars and lipids in patients with diabetes and some studies had shown the unpredictable effects of compounds containing omega 3 in predisposing the subjects to lipid peroxidation in aerobic conditions. This has been reported to happen in the absence of antioxidants. On the other hand, some studies have pointed out that the PUFAs themselves could act as antioxidants under in vivo conditions if they are taken with sufficient amounts of vitamin E; therefore, under this condition, the first reactive oxygen species scavenging system operates (22) (23) (24) . On these grounds, while we were administering vitamin E, we evaluated this effect in some of the groups and in addition to measuring vitamin E, we also measured the total serum antioxidants and antioxidants such as glutathione peroxidase, glutathione oxidase, catalase, superoxide dismutase and also malondialdehyde and protein carbonyl levels as biomarkers for oxidative stress (25) .
After three months of intervention, significant increases in serum adiponectin (ADP) concentration in EPA supplemented groups were similar to those observed by Fernández R. et al. (26) and reported by Havel et al. (27) by consumption of fish oil. Flachs et al. showed that ADP gene expression was stimulated by dietary EPA; hence, the serum concentrations of the substance increased (28) .
Although Perez et al. believed that serum leptin concentration was related to intake of EPA containing foods and it had no effects on serum ADP serum concentration. Nevertheless, if the same amount of EPA intake (2 grams) is adjusted for adiposity (adiponectin concentration per content of white adipose tissue in grams), we will notice a remarkable rise in serum adiponectin concentration following daily consumption of 2 grams of EPA (P=0.05) (29). However, a different study on patients with nonalcoholic steatohepatitis (NASH) showed no difference in serum level of ADP using 2.7 g EPA for a year (30) . In our study, the increase in serum ADP serum concentration could be due to administration of 2 g of EPA for three months.
Researches (36) . The initial reports showed that the increase in serum glucose and HbA1c concentrations were accompanied by high intakes of fish oil (10 g or more daily) which is consistent with other studies with various amounts (3.3g, 5.5g, and 10g) of EPA and docosahexaenoic acid (DHA) intake in different societies following worries about omega-3 in increasing the glycemic profiles (37) (38) (39) (40) (41) . While most of those studies were based on 1-2 g doses, not only the intervention showed no undesirable effect on glycemic profile but it also improved it (42) . In the present study in which 2 g of pure EPA was used, glycemic profile improved in the patients, which is in consistency with other studies (42) . EPA also decreases the deposition of fatty acids in skeletal muscles and β cells of the pancreas; therefore, it decreases the insulin resistance and finally leads to the control of serum glucose concentration (32) . As the placebo group did not have any intervention compared to their prestudy period and this could be the reason why patients with diabetes should not only be cared for their diet, but also for supplements, or even EPA supplement for the better control of their blood sugar.
Mori et al. indicate that a combination of food regimen containing fish and dieting could improve glucose and insulin metabolism (31) . Administering EPA, Morishita found that reduction of plasma insulin and blood sugar and increased sensitivity to insulin were so prominent that he suggested in conjunction with medications, diet and physical activity in patients with type 2 diabetes (43) . As the placebo group in his study had had an omega-3 deficient and they were instead supplemented with omega-6, the glucose metabolism indicators not only have not improved, but also they have increased instead. Moreover, research on mice indicates that consumption of corn oil results in increases in weight, total body fat, total abdominal fat and cytokines such as Interleukin 6 and TNF-α, which both are among the substances to increase blood sugar and enhance insulin resistance (33) . As Shab-Bidar et al. and Ford ES have previously stated there is some discrepancy among the results of association studies, which have reported mixed findings regarding blood concentrations of vitamin E and the incidence of diabetes (44, 45) . Similarly, there is no consistency between clinical trials, with some reporting possible beneficial effects of vitamin E supplementation in diabetic patients and others not (45, 46) . The findings of previous studies suggest that vitamin E has a beneficial effect only among people who do not use dietary supplements regularly and obtain their vitamins from the nutritional intake of food (47) , as well as in those who suffer from particularly high levels of oxidative stress and/ or have poor vitamin E status (47) . As Shab-Bidar et al. have previously stated it seems that the use of pharmacological doses of vitamin E does not confer additional benefits and has little clinical significance (44) . in conclusion, EPA is a food supplement that could be taken safely with blood glucose lowering drugs in patients with diabetes type II. It provides the kind of fatty acid whose absence plays an etiologic role in diabetes and related diseases.
